Research supported by Starr Cancer Consortium awards is reported in the following publications. The Starr Cancer Consortium is funded by the Starr Foundation.
Resveratrol-salicylate derivatives as selective DNMT3 inhibitors and anticancer agents.
Site-Specific Bioorthogonal Labeling for Fluorescence Imaging of Intracellular Proteins in Living Cells.
Cutoff Suppresses RNA Polymerase II Termination to Ensure Expression of piRNA Precursors.
A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations.
Greater Than the Sum of Parts: Complexity of the Dynamic Epigenome.
H4K20me0 marks post-replicative chromatin and recruits the TONSL-MMS22L DNA repair complex.
Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma.
RNA editing generates cellular subsets with diverse sequence within populations.
Structural basis underlying viral hijacking of a histone chaperone complex.
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma.
Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.
Emerging concepts of epigenetic dysregulation in hematological malignancies.
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.
Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival.